Launch One Acquisition Corp

What Launch One Acquisition Corp does

Launch One Acquisition Corp is a Special Purpose Acquisition Company (SPAC) incorporated in 2024 and headquartered at 180 Grand Avenue, Suite 1530, Oakland, California. The company filed an S-1 registration statement with the SEC and is structured to identify, acquire, or merge with a private operating business in order to take it public. As of the input data, the SPAC has no operating revenue, no employees on record, and no commercial products; its sole asset under management is the pursuit of a qualifying business combination. The leadership team consists of Chairman Ryan Gilbert, CEO Chris Ehrlich, and CFO Jurgen van de Vyver, with nominated directors Brian G. Atwood, Rod Ferguson Ph.D., and Risa Stack Ph.D. expected to join the board.

On June 25, 2025, Launch One Acquisition Corp announced a proposed business combination with Minovia Therapeutics Ltd., an Israeli clinical-stage biotechnology company developing mitochondrial augmentation technology. The combined entity is intended to list on Nasdaq and to target the $1 trillion-plus mitochondrial and longevity markets. Minovia's lead product candidate, MNV-201, is a mitochondrial augmentation therapy in development for myelodysplastic syndrome (MDS) and has demonstrated a high safety profile and clinical benefit in a Phase 1b trial in low-risk MDS patients; it has also received FDA Orphan Drug Designation for MDS. Financial terms of the combination are undisclosed in the input.

As a pre-combination SPAC, Launch One Acquisition Corp generates no revenue and has no pricing model or go-to-market motion; its economics derive entirely from the capital held in its trust account and from any equity, debt, or warrant instrument issued to effect a business combination. Post-closing, the combined company's revenue mechanics would depend on commercialization of MNV-201 and follow-on mitochondrial therapies, none of which are commercially approved today.

Name

Launch One Acquisition Corp

Legal name

Launch One Acquisition Corp

Website

https://launchoneacquisitioncorp.com

Company type

Private

Founded year

2024

Operating status

Operating

Short description

Launch One Acquisition Corp is a 2024 SPAC headquartered in Oakland, CA, that on June 25, 2025 announced a proposed business combination with Minovia Therapeutics Ltd. to create a Nasdaq-listed mitochondrial therapy company targeting the $1 trillion-plus mitochondrial and longevity markets.

Ownership category

akta.pro rank

Product category

Special Purpose Acquisition Vehicle (Blank Check Company)

NAICS

Management Consulting Services (54161), Management of Companies and Enterprises (551)

SIC

Security Brokers, Dealers & Flotation Companies (6211), Services-Management Services (8741)

akta.pro primary industry

Capital Markets Advisory (IPO Readiness, SPAC, ECM/DCM Advisory) (BPAHAOAL)

akta.pro secondary industries

Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs) (BPAHAOAG), Buy-Side Search & Acquisition Advisory (FSAEAIAD)

Keywords

• Special purpose acquisition
• Blank check company
• Business combination
• Initial public offering
• Equity capital markets

Headquarters

HQ city

Oakland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Core offering

Launch One Acquisition Corp is a pre-IPO Special Purpose Acquisition Company (SPAC) formed to identify and complete a business combination with a target company. The company has announced a proposed business combination with Minovia Therapeutics, an Israeli clinical-stage biotechnology company developing mitochondrial augmentation therapies, with the announcement of the proposed deal dated June 25, 2025. Until a business combination is completed, Launch One is a shell/blank check entity with no operating business.

Product overview

Launch One Acquisition Corp is a Special Purpose Acquisition Company (SPAC) planning a proposed business combination with Minovia Therapeutics Ltd. to create a Nasdaq-listed mitochondrial therapy company. The combined entity would operate in the mitochondrial and longevity markets, estimated at over $1 trillion. Minovia's lead product candidate MNV-201 is a mitochondrial augmentation technology being developed for myelodysplastic syndrome (MDS) treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• MNV-201 (target company lead candidate, pre-clinical / planned IND stage)

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Minovia Therapeutics Ltd.coreStrategic or Co-development Partner · 25 June 2025Launch One Acquisition Corp announced a proposed business combination with Minovia Therapeutics Ltd. to create a Nasdaq-listed mitochondrial therapy company. The combined entity will target the $1 trillion+ mitochondrial and longevity markets. Minovia Therapeutics specializes in mitochondrial augmentation technology with lead product MNV-201 for myelodysplastic syndrome (MDS).

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• ARYA Sciences Acquisition Corp: Biotech-focused SPAC that completed a business combination with Dyne Therapeutics; directly comparable as a healthcare/biotech SPAC sponsor pursuing a single life-sciences target.
• Perceptive Capital Solutions Corp: Healthcare-focused SPAC sponsor with a similar single-target identification model; directly comparable in scope and biotech/healthcare deal focus.
• GS Acquisition Holdings Corp: SPAC sponsored by Goldman Sachs that completed a merger with INEOS Energy; directly comparable as a large SPAC pursuing a major business combination.
• Brookline Capital Acquisition Corp: SPAC structure with a similar single-target identification model; directly comparable to Launch One's blank-check structure and merger execution path.
• dMY Technology Group, Inc. Technology-focused SPAC sponsor that completed mergers with multiple targets; directly comparable as a SPAC sponsor pursuing a single strategic acquisition.
• Silver Spike Acquisition Corp: Life sciences and cannabis-focused SPAC sponsor; directly comparable as a SPAC pursuing a healthcare-adjacent target company.
• Health Sciences Acquisitions Corporation: Healthcare-focused SPAC pursuing a business combination with a life-sciences target; directly comparable structure and sector focus to Launch One Acquisition Corp.

Broad incumbents

• EarlyBirdCapital, Inc. Investment bank specializing in SPAC IPOs and advisory; broadly comparable as a SPAC ecosystem incumbent that supports similar blank-check structures and business combinations.
• Cohen & Company Inc. Diversified financial services firm with a dedicated SPAC advisory and capital markets practice; broadly comparable as a SPAC ecosystem participant and advisor to similar transactions.

Emerging players

• Minovia Therapeutics Ltd. Israeli biotech developing mitochondrial augmentation therapy with lead asset MNV-201; the actual target company of Launch One's announced business combination and a key strategic reference point.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Launch One Acquisition Corp